Related Experiment Video
Updated: May 22, 2026
11:49
Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
Published on: May 2, 2013
Interleukin-2 receptor antagonist does not decrease biopsy-proven acute rejection among adult Chinese kidney
Ying-Chih Lo1, Hao-Chung Ho, Ming-Ju Wu
1Division of Nephrology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
Renal Failure
|May 16, 2012
Summary
Interleukin-2 receptor antagonist (IL2RA) induction therapy showed no benefit in preventing biopsy-proven acute rejection (BPAR) for Chinese kidney transplant recipients. Routine IL2RA use may not be as effective as previously thought in this population.
Area of Science:
- Nephrology
- Immunosuppression
- Transplantation
Background:
- Interleukin-2 receptor antagonist (IL2RA) is a common induction therapy for renal transplant recipients.
- The efficacy of IL2RA in Chinese populations requires further investigation.
Purpose of the Study:
- To evaluate the impact of IL2RA on biopsy-proven acute rejection (BPAR) in Chinese renal transplant recipients.
- To assess secondary outcomes including acute rejection rate, delayed graft function, post-transplant diabetes mellitus, and malignancy.
Main Methods:
- Retrospective study of 238 Chinese renal transplant recipients (2004-2009).
- Patients were divided into IL2RA (basiliximab or daclizumab) and no induction therapy groups.
- Cox proportional hazard analysis was used for multivariate analysis.
Main Results:
- No significant difference in BPAR was observed between the IL2RA and no induction therapy groups.
- Secondary outcomes, including acute rejection rates, delayed graft function, post-transplant diabetes mellitus, and malignancy, were also similar between groups.
- Multivariate analysis confirmed no benefit of IL2RA on BPAR after adjusting for covariates.
Conclusions:
- IL2RA induction therapy did not demonstrate a benefit in reducing BPAR in adult Chinese kidney transplant recipients.
- The routine use of IL2RA in this specific patient population may not be as effective as anticipated.
- Further research is necessary to clarify the role of IL2RA in Chinese kidney transplant recipients.
Related Concept Videos
01:26Kidney Transplant II: Surgical Procedure
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...
01:28Kidney Transplant I: Introduction
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
01:16Kidney Transplant III: Nursing Management
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...